Fig. 1 MEDI9904/PIMS19990739 Anti-HBs response at day 14 post II

Results on individual sera (EU/ml)




Fig. 2 MEDI9904/PIMS19990739
Anti-PD1/3 16E7 response at day 14 post II

Results on individual sera (EU/ml)




Fig. 3 MEDI9904/PIMS19990739 Anti-VLP16 response at day 14 post II

Results on individual sera (EU/ml)




Fig. 4 MEDI9904/PIMS19990739 Anti-VLP18 response at day 14 post II

Results on individual sera (EU/ml)





Fig. 5 MEDI9904/PIMS19990739 Cytokine results - day 14 post II

IFN-γ production after in vitro stimulation with HBs

A)



IL-5 production after in vitro stimulation with HBs

B)





Fig. 6 MEDI9904/PIMS19990739 Cytokine results - day 14 post II

IFN-γ production after in vitro stimulation with PD 1/3 E7



IL-5 production after in vitro stimulation with PD 1/3 16E7





Fig. 7 MEDI9904/PIMS19990739 Lymphoproliferation results

In vitro stimulation with VLP16 at day 14 post II

A)




B)

	Group A	Group B	Group G	Group H
10	25281	3629	32328	30735
1	18946	3400	21156	19528
0.1	13568	3486	17910	21575
0.01	13118	2797	14579	16747
0.001	12381	2966	13901	16595
0	3286	3319	3392	4736

Fig. 8 MEDI9904/PIMS19990739 Lymphoproliferation results

In vitro stimulation with VLP18 at day 14 post II




	Group A	Group B	Group G	Group H
10	22299	4489	27806	33396
1	17870	3978	21945	26047
0.1	18864	4027	22080	25173
0.01	21429	4086	17243	27390
0.001	21066	4382	19893	21502
0	4113	4501	3399	3996

Fig. 9 MEDI9904/PIMS19990739 Cytokine results - day 14 post II

IFN-γ production after in vitro stimulation with VLP16

A)



IL-5 production after in vitro stimulation with VLP16

B)





Fig. 10


VLP18 10µg/ml
VLP18 1µg/ml
No antigen
IL5 pg/ml
35000
30000
25000
20000
15000
10000
5000
0
Group A
Group G
Group H
Groups